Meta-Analysis of Optimal Allometric Exponent for Indexing of Echocardiographic Left Ventricular Mass

2020 ◽  
Vol 33 (3) ◽  
pp. 401-403.e1
Author(s):  
Anders Sahlén ◽  
See Hooi Ewe ◽  
Zee Pin Ding
Keyword(s):  
Left Ventricular Mass ◽  
Meta Analysis ◽  
Left Ventricular ◽  
Allometric Exponent ◽  
Ventricular Mass

scholarly journals Left Ventricular Mass Regression, All-Cause and Cardiovascular Mortality in Chronic Kidney Disease: A Meta-Analysis

2021 ◽  
Author(s):  
Kevin C. Maki ◽  
Meredith L. Wilcox ◽  
Mary R. Dicklin ◽  
Rahul Kakkar ◽  
Michael H. Davidson
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Left Ventricular Mass ◽  
Cardiovascular Mortality ◽  
Meta Analysis ◽  
Left Ventricular ◽  
Secondary Outcome ◽  
Ventricular Mass ◽  
Increased Risk ◽  
All Cause Mortality

Abstract Background Cardiovascular disease is an important driver of the increased mortality associated with chronic kidney disease (CKD). Higher left ventricular mass (LVM) predicts increased risk of adverse cardiovascular outcomes and total mortality, but previous reviews have shown no clear association between intervention-induced LVM change and all-cause or cardiovascular mortality in CKD. Methods The primary objective of this meta-analysis was to investigate whether treatment-induced reductions in LVM over periods ≥ 12 months were associated with all-cause mortality in patients with CKD. Cardiovascular mortality was investigated as a secondary outcome. Measures of association in the form of relative risks (RRs) with associated variability and precision (95% confidence intervals [CIs]) were extracted directly from each study, when reported, or were calculated based on the published data, if possible, and pooled RR estimates were determined. Results The meta-analysis included 38 trials with duration ≥ 12 months: 6 of erythropoietin stimulating agents treating to higher vs. lower hemoglobin targets, 10 of renin-angiotensin-aldosterone system inhibitors vs. placebo or another blood pressure lowering agent, 14 of modified hemodialysis regimens, and 8 of other types of interventions. All-cause mortality was reported in 116/2385 (4.86%) subjects in intervention groups and 161/2404 (6.70%) subjects in control groups. The pooled RR estimate of the 24 trials ≥ 12 months with ≥ 1 event in ≥ 1 group was 0.72 (95% CI 0.57 to 0.91, p = 0.005), with little heterogeneity across studies. Directionalities of the associations in intervention subgroups were the same. Sensitivity analyses of ≥ 6 months (31 trials), ≥ 9 months (26 trials), and > 12 months (9 trials), and including studies with no events in either group, demonstrated similar risk reductions to the primary analysis. The point estimate for cardiovascular mortality was similar to all-cause mortality, but not statistically significant: RR 0.66, 95% CI 0.38 to 1.15. Conclusions These results suggest that LVM regression may be a useful surrogate marker for benefits of interventions intended to reduce mortality risk in patients with CKD.

Meta-Analysis of Valve Hemodynamics and Left Ventricular Mass Regression for Stentless Versus Stented Aortic Valves

2007 ◽  
Vol 84 (1) ◽  
pp. 73-78 ◽  
Author(s):  
Babu Kunadian ◽  
Kunadian Vijayalakshmi ◽  
Andrew R. Thornley ◽  
Mark A. de Belder ◽  
Steven Hunter ◽  
...  
Keyword(s):  
Left Ventricular Mass ◽  
Meta Analysis ◽  
Left Ventricular ◽  
Aortic Valves ◽  
Ventricular Mass

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

2003 ◽  
Vol 115 (1) ◽  
pp. 41-46 ◽  
Author(s):  
Arnfried U Klingbeil ◽  
Markus Schneider ◽  
Peter Martus ◽  
Franz H Messerli ◽  
Roland E Schmieder
Keyword(s):  
Essential Hypertension ◽  
Left Ventricular Mass ◽  
Meta Analysis ◽  
Left Ventricular ◽  
Ventricular Mass
Sign in / Sign up

Export Citation Format

Share Document